摘要目的:通过检测成纤维细胞活化蛋白-α(FAP-α)、组成型光形态发生因子9信号复合体亚基6(CSN6)在膀胱尿路上皮癌组织中的表达，解析其在膀胱尿路上皮癌中的临床意义。方法:选择2015年1月至2017年5月本院收治的膀胱尿路上皮癌患者74例为研究对象，同期选取在本院经膀胱镜检查排除膀胱移行细胞癌，同时患有其他泌尿系统疾病并接受手术治疗留取正常膀胱组织的患者61例为对照组。免疫组织化学法检测两组受试者膀胱组织中的FAP-α、CSN6水平；分析膀胱尿路上皮癌组织中FAP-α、CSN6表达及二者与一般临床资料的相关性；对所有患者进行术后3年内随访，分析FAP-α、CSN表达对膀胱尿路上皮癌患者预后的影响；Cox分析影响膀胱尿路上皮癌预后不良的危险因素。结果:与正常膀胱组织相比，膀胱尿路上皮癌组织中FAP-α、CSN6蛋白具有较高的阳性表达率( P<0.05)；膀胱尿路上皮癌组织中FAP-α、CSN6蛋白的表达与患者病理分级及临床分期有相关性( P<0.05)；FAP-α阳性表达组3年内复发率高于阴性表达组( P<0.05)；CSN6阳性表达组3年内复发率高于阴性表达组( P<0.05)；多因素Cox分析表明，病理分级、临床分期以及膀胱尿路上皮癌组织中FAP-α、CSN6阳性表达是影响膀胱尿路上皮癌患者不良预后的危险因素( P<0.05)。 结论:FAP-α、CSN6可能参与膀胱尿路上皮癌的发病机制，有望成为膀胱尿路上皮癌潜在的治疗靶点。

abstractsObjective:To detect the levels of FAP-α and CSN6 in bladder urothelial carcinoma and analyze the clinical significance of FAP-α and CSN6 in bladder urothelial carcinoma.Methods:From January 2015 to May 2017, 74 patients with bladder urothelial carcinoma in our hospital were selected as the study subjects, at the same time, 61 patients without bladder urothelial carcinoma excluded by cystoscopy but with other urinary system diseases, treated by operation and retained normal bladder tissues in our hospital were taken as control group. The levels of FAP-α and CSN6 were detected by immunohistochemistry; the expressions of FAP-α and CSN6 in bladder urothelial carcinoma and their correlation with general clinical data were analyzed; all patients were followed-up for 3 years to analyze the effects of FAP-α and CSN expressions on the prognosis of bladder urothelial carcinoma; and Cox was used to analyze the risk factors for poor prognosis of bladder urothelial carcinoma.Results:Compared with those in normal bladder tissue, FAP-α and CSN6 proteins in bladder urothelial carcinoma tissue had higher positive expression rates ( P<0.05); the expressions of FAP-α and CSN6 proteins in bladder urothelial carcinoma were related to pathological grade and clinical stage ( P<0.05); the three-year recurrence rate of FAP-α positive group (52.9%) was higher than that of negative group (26.1%); and the three-year 36 recurrence rate of CSN6 positive group (55.1%) was higher than that of negative group (24.0%); in addition, multivariate Cox analysis showed that pathological grade, clinical stage and positive expressions of FAP-α and CSN6 were the risk factors for poor prognosis of bladder urothelial carcinoma ( P<0.05). Conclusions:FAP-α and CSN6 may be involved in the pathogenesis of bladder urothelial carcinoma and may be potential therapeutic targets for bladder urothelial carcinoma.